Danaher (DHR) Jumps on Improved Q3 Earnings

We recently published 10 Stocks Leaving Wall Street in the Dust. Danaher Corp. (NYSE:DHR) is one of the best performers on Tuesday.

Danaher bounced back by 5.94 percent on Tuesday to close at $220.77 apiece after achieving an improved earnings performance in the third quarter of the year.

In an updated report, Danaher Corp. (NYSE:DHR) said net income jumped by 11 percent to $908 million from $818 million in the same period last year. Sales grew by 4.4 percent to $6.05 billion from $5.798 billion year-on-year.

For the nine-month period, net income declined by 14 percent to $2.417 billion from $2.813 billion in the same comparable period, while sales inched up by 2.27 percent to $17.73 billion from $17.3 billion year-on-year.

Danaher Corp. (NYSE:DHR) President and CEO Rainer Blair said he was encouraged by the results, driven by Danaher Business System-driven execution coupled with continued momentum in the bioprocessing business and better-than-anticipated respiratory revenue at Cepheid.

“We’re investing in breakthrough innovation, enhancing our commercial execution, and driving meaningful productivity gains across our businesses. We believe these efforts will strengthen our long-term competitive position and help to solve some of the world’s most difficult healthcare challenges,” he added.

For the full-year 2025, Danaher Corp. (NYSE:DHR) reaffirmed its guidance of $7.70 to $7.80 for adjusted diluted net earnings per common share. This assumes that non-GAAP core revenue will grow by low single digits year-on-year.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.